In addition, there are also differences in the rate of ctDNA detection in early disease according to the subtype of BC, with human epidermal growth factor receptor 2 (HER2) positive and triple-negative breast cancer (TNBC) having higher levels of shed ctDNA compared to luminal BC14,15. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.